CY2013029PI1 - Νεα παραγωγα ινσουλινης - Google Patents

Νεα παραγωγα ινσουλινης

Info

Publication number: CY2013029PI1
Authority: CY; Cyprus
Prior art keywords: insulin derivatives; new insulin; new; derivatives; insulin
Prior art date: 2003-08-05

Application number

CY2013029C

Other languages

English (en)

Original Assignee

Novo Nordisk A/S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-05

Filing date

2013-07-08

Publication date

2015-11-04

2013-07-08 Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S

2015-11-04 Publication of CY2013029PI2 publication Critical patent/CY2013029PI2/el

2015-11-04 Publication of CY2013029PI1 publication Critical patent/CY2013029PI1/el

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Diabetes (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Toxicology (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

CY2013029C 2003-08-05 2013-07-08 Νεα παραγωγα ινσουλινης CY2013029PI1 (el)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DKPA200301129		2003-08-05
US49545103P	2003-08-14	2003-08-14
EP04739008A EP1660531A2 (en)	2003-08-05	2004-07-22	Novel insulin derivatives

Publications (2)

Publication Number	Publication Date
CY2013029PI2 CY2013029PI2 (el)	2015-11-04
CY2013029PI1 true CY2013029PI1 (el)	2015-11-04

Family

ID=34117520

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
CY20131100259T CY1113850T1 (el)	2003-08-05	2013-03-28	Νεα παραγωγα ινσουλινης
CY2013027C CY2013027PI2 (el)	2003-08-05	2013-07-04	Νεα παραγωγα ινσουλινης
CY2013029C CY2013029PI1 (el)	2003-08-05	2013-07-08	Νεα παραγωγα ινσουλινης
CY2013029C CY2013029I2 (el)	2003-08-05	2023-12-28	Νεα παραγωγα ινσουλινης
CY2013027C CY2013027I2 (el)	2003-08-05	2024-01-31	Νεα παραγωγα ινσουλινης

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
CY20131100259T CY1113850T1 (el)	2003-08-05	2013-03-28	Νεα παραγωγα ινσουλινης
CY2013027C CY2013027PI2 (el)	2003-08-05	2013-07-04	Νεα παραγωγα ινσουλινης

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
CY2013029C CY2013029I2 (el)	2003-08-05	2023-12-28	Νεα παραγωγα ινσουλινης
CY2013027C CY2013027I2 (el)	2003-08-05	2024-01-31	Νεα παραγωγα ινσουλινης

Country Status (18)

Country	Link
US (3)	US7615532B2 (el)
EP (3)	EP2264065B1 (el)
JP (1)	JP4463814B2 (el)
KR (1)	KR101159559B1 (el)
AU (2)	AU2004261353B2 (el)
BE (2)	BE2013C035I2 (el)
BR (1)	BRPI0413276B8 (el)
CA (1)	CA2531988C (el)
CY (5)	CY1113850T1 (el)
FR (2)	FR13C0035I2 (el)
HU (1)	HUS1300033I1 (el)
IL (1)	IL172980A (el)
LU (2)	LU92213I2 (el)
MX (1)	MXPA06001283A (el)
NO (5)	NO340925B1 (el)
PL (1)	PL2107069T3 (el)
RU (1)	RU2518460C2 (el)
WO (1)	WO2005012347A2 (el)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1648933B1 (en) *	2003-07-25	2009-06-17	ConjuChem Biotechnologies Inc.	Long lasting insulin derivatives and methods thereof
EP2264065B1 (en)	2003-08-05	2017-03-08	Novo Nordisk A/S	Novel insulin derivatives
WO2006082205A1 (en)	2005-02-02	2006-08-10	Novo Nordisk A/S	Insulin derivatives
ES2428510T3 (es)	2005-02-02	2013-11-08	Novo Nordisk A/S	Derivados de insulina
US20090074882A1 (en)	2005-12-28	2009-03-19	Novo Nordisk A/S	Insulin compositions and method of making a composition
EP1991576B1 (en) *	2006-02-27	2010-09-29	Novo Nordisk A/S	Insulin derivatives
WO2007104736A2 (en) *	2006-03-13	2007-09-20	Novo Nordisk A/S	Acylated single chain insulin
US8293965B2 (en)	2006-04-28	2012-10-23	Kimberly-Clark Worldwide, Inc.	Antimicrobial site dressings
CN101437849B (zh) *	2006-05-09	2015-09-30	诺沃-诺迪斯克有限公司	胰岛素衍生物
EP2024390B1 (en)	2006-05-09	2015-08-19	Novo Nordisk A/S	Insulin derivative
AU2007247109B2 (en) *	2006-05-09	2012-03-15	Novo Nordisk A/S	Insulin derivative
JP5097900B2 (ja) *	2006-06-27	2012-12-12	独立行政法人物質・材料研究機構	有機酸又はこれらの誘導体の活性エステル体の製造方法
WO2008015099A2 (en)	2006-07-31	2008-02-07	Novo Nordisk A/S	Pegylated, extended insulins
KR101699370B1 (ko)	2006-09-22	2017-02-14	노보 노르디스크 에이/에스	프로테아제 내성 인슐린 유사체
EP2502618A3 (en)	2007-04-30	2012-10-03	Novo Nordisk A/S	Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
EP2164466A1 (en)	2007-06-01	2010-03-24	Novo Nordisk A/S	Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
EP2164459A1 (en) *	2007-06-01	2010-03-24	Novo Nordisk A/S	Stable non-aqueous pharmaceutical compositions
ES2744384T3 (es) *	2007-06-13	2020-02-24	Novo Nordisk As	Formulación farmacéutica que comprende un derivado de insulina
EP2178912B1 (en)	2007-08-15	2015-07-08	Novo Nordisk A/S	Insulin analogues with an acyl and aklylene glycol moiety
CN101784563B (zh)	2007-08-15	2015-02-04	诺沃-诺迪斯克有限公司	具有包括含亚烷基二醇的氨基酸的重复单位的酰基部分的胰岛素
CN101157725B (zh) *	2007-10-24	2012-07-25	中国药科大学	人胰岛素类似物的制备方法及用途
US8710000B2 (en)	2007-11-08	2014-04-29	Novo Nordisk A/S	Insulin derivative
PT2597103T (pt)	2007-11-16	2017-02-08	Novo Nordisk As	Composições farmacêuticas contendo insulina e um péptido insulinotrófico
US9260502B2 (en)	2008-03-14	2016-02-16	Novo Nordisk A/S	Protease-stabilized insulin analogues
US8691759B2 (en)	2008-03-18	2014-04-08	Novo Nordisk A/S	Protease stabilized, acylated insulin analogues
ES2561208T3 (es)	2008-09-12	2016-02-25	Novo Nordisk A/S	Método de acilación de un péptido o una proteína
JP4959005B2 (ja) *	2008-10-30	2012-06-20	ノボ・ノルデイスク・エー／エス	毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
MX2011007544A (es)	2009-01-23	2011-08-12	Novo Nordisk As	Derivados de factor de crecimiento de fibroblastos 21 (fgf21) con ligante de albumina a-b-c-d-e- y su uso.
EP2493919A1 (en)	2009-10-30	2012-09-05	Novo Nordisk A/S	Derivatives of cgrp
MX2012007806A (es) *	2010-01-12	2012-08-01	Novo Nordisk As	Composiciones farmaceuticas para administracion oral de peptidos de insulina.
US9234192B2 (en)	2010-02-16	2016-01-12	Novo Nordisk A/S	Conjugated proteins
WO2011101261A2 (en)	2010-02-16	2011-08-25	Novo Nordisk A/S	Purification method
EP2569002B1 (en)	2010-05-10	2016-10-26	Novo Nordisk A/S	Process for the preparation of insulin-zinc complexes
WO2011146974A1 (en)	2010-05-25	2011-12-01	Monash University	Methods for the synthesis of alkyne-containing dicarba bridges in peptides
JP5973427B2 (ja)	2010-06-23	2016-08-23	ノヴォノルディスクアー／エス	追加のジスルフィド結合を含有するインスリン類似体
MX337549B (es) *	2010-06-23	2016-03-10	Novo Nordisk As	Derivados de insulina que contienen enlaces disulfuro adicionales.
WO2011161083A1 (en)	2010-06-23	2011-12-29	Novo Nordisk A/S	Human insulin containing additional disulfide bonds
US20140315797A1 (en)	2010-10-15	2014-10-23	Peter Madsen	Novel N-Terminally Modified Insulin Derivatives
DK2632478T3 (da) *	2010-10-27	2019-10-07	Novo Nordisk As	Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
AU2011322495A1 (en) *	2010-10-27	2013-04-11	Novo Nordisk A/S	Treating diabetes melitus using insulin injections administered with varying injection intervals
JP2013545782A (ja)	2010-12-14	2013-12-26	ノヴォノルディスクアー／エス	長時間作用型インスリンと組み合わせた速効型インスリン
WO2012110422A1 (en)	2011-02-15	2012-08-23	Novo Nordisk A/S	Long-acting il-1 receptor antagonists
AU2012234276A1 (en) *	2011-03-28	2013-08-29	Novo Nordisk A/S	Novel glucagon analogues
JP6030630B2 (ja)	2011-04-14	2016-11-24	ノヴォノルディスクアー／エス	経口ペプチド送達のための脂肪酸アシル化アミノ酸
US9260503B2 (en)	2011-06-15	2016-02-16	Novo Nordisk A/S	Multi-substituted insulins
RU2610175C2 (ru)	2011-09-23	2017-02-08	Ново Нордиск А/С	Новые аналоги глюкагона
KR20140104994A (ko) *	2011-12-15	2014-08-29	샹하이 헨그루이 파마수티컬 컴퍼니 리미티드	인간 인슐린 유사체 및 이의 아실화 유도체
EP2794648A1 (en)	2011-12-21	2014-10-29	Novo Nordisk A/S	N-terminally modified insulin derivatives
KR20150002777A (ko)	2012-04-11	2015-01-07	노보 노르디스크 에이/에스	인슐린 제제
US20160031962A1 (en) *	2012-04-20	2016-02-04	Kleomenis K. Barlos	Solid phase peptide synthesis of insulin using side chain achored lysine
AU2013255880B2 (en)	2012-05-01	2017-07-20	Novo Nordisk A/S	Pharmaceutical composition
WO2014009316A1 (en)	2012-07-09	2014-01-16	Novo Nordisk A/S	Novel use of insulin derivatives
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP6285447B2 (ja)	2012-10-17	2018-02-28	ノヴォノルディスクアー／エス	経口ペプチド送達用の脂肪酸アシル化ｄ−アミノ酸
CA2894765A1 (en)	2012-12-21	2014-06-26	Sanofi	Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
EP2976096B1 (en) *	2013-03-20	2019-02-27	Novo Nordisk A/S	Insulin dosing regimen
MY174727A (en)	2013-04-18	2020-05-11	Novo Nordisk As	Stable, protracted glp-1/glucagon receptor co-agonists for medical use
EP2991672A1 (en)	2013-04-30	2016-03-09	Novo Nordisk A/S	Novel administration regime
GB201315335D0 (en)	2013-08-29	2013-10-09	Of Singapore	Amino diacids containing peptide modifiers
ES2676065T3 (es)	2013-10-07	2018-07-16	Novo Nordisk A/S	Nuevo derivado de un análogo de la insulina
FR3013049B1 (fr)	2013-11-14	2015-11-13	You-Ping Chan	Analogue de l'insuline glargine
TW201609796A (zh)	2013-12-13	2016-03-16	賽諾菲公司	非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609799A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／ｇｉｐ受體促效劑
EP3080150B1 (en)	2013-12-13	2018-08-01	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609797A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／升糖素受體促效劑
CA2939763A1 (en)	2014-02-18	2015-08-27	Novo Nordisk A/S	Stable glucagon analogues and use for treatment of hypoglycaemia
AR099569A1 (es)	2014-02-28	2016-08-03	Novo Nordisk As	Derivados de insulina y los usos médicos de estos
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
CN106536547A (zh)	2014-06-04	2017-03-22	诺和诺德股份有限公司	用于医疗用途的glp‑1/胰高血糖素受体共激动剂
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
WO2017032795A1 (en)	2015-08-25	2017-03-02	Novo Nordisk A/S	Novel insulin derivatives and the medical uses hereof
EP3341402A1 (en)	2015-08-25	2018-07-04	Novo Nordisk A/S	Novel insulin derivatives and the medical uses hereof
WO2018024186A1 (zh)	2016-08-02	2018-02-08	江苏恒瑞医药股份有限公司	一种人胰岛素或其类似物的酰化衍生物
EP3544683A1 (en)	2016-11-28	2019-10-02	Novo Nordisk A/S	Insulin degludec in cardiovascular conditions
CN110099719A (zh)	2016-11-28	2019-08-06	诺和诺德股份有限公司	用于改善血糖控制以及减少急性和长期糖尿病并发症的德谷胰岛素
WO2018096164A1 (en)	2016-11-28	2018-05-31	Novo Nordisk A/S	Insulin degludec for treating diabetes
PE20210857A1 (es)	2016-12-16	2021-05-18	Novo Nordisk As	Composiciones farmaceuticas que contienen insulina
JOP20190273A1 (ar)	2017-05-26	2019-11-24	Lilly Co Eli	مركب إنسولين معالج بأسيل
JP2021513330A (ja)	2018-02-09	2021-05-27	江蘇恒瑞医薬股▲ふん▼有限公司	ヒトインスリンアナログのコドン最適化前駆体遺伝子およびシグナルペプチド遺伝子
EP3805257A4 (en)	2018-05-24	2022-03-16	Jiangsu Hengrui Medicine Co., Ltd.	METHOD OF PRODUCTION OF A PRECURSOR OF RECOMBINANT HUMAN INSULIN OR ANALOGUE THEREOF
US10335464B1 (en)	2018-06-26	2019-07-02	Novo Nordisk A/S	Device for titrating basal insulin
JP7410891B2 (ja)	2018-06-26	2024-01-10	ノボ・ノルデイスク・エー／エス	基礎インスリン滴定のための投与推奨を提供するシステム
KR102666154B1 (ko)	2018-08-08	2024-05-20	주식회사 대웅제약	지속형 인슐린 아날로그 및 그 복합체
KR20200080748A (ko)	2018-12-27	2020-07-07	주식회사 폴루스	음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법
KR20200080747A (ko)	2018-12-27	2020-07-07	주식회사 폴루스	인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법
TWI844709B (zh)	2019-07-31	2024-06-11	美商美國禮來大藥廠	鬆弛素(relaxin)類似物及其使用方法
CN118480114A (zh)	2019-12-30	2024-08-13	甘李药业股份有限公司	胰岛素衍生物
US20250000948A1 (en)	2021-11-15	2025-01-02	Adocia	Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299057A1 (en)	2022-06-30	2024-01-03	Adocia	Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4180060A1 (en)	2021-11-15	2023-05-17	Adocia	Solid compositions comprising a peptide or a protein and an acylated amino acid
WO2023143458A1 (zh)	2022-01-28	2023-08-03	甘李药业股份有限公司	酰化胰岛素
EP4299071A1 (en)	2022-07-01	2024-01-03	Adocia	Compositions comprising a peptide or a protein and an acylated amino acid

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1212679B (de)	1957-08-03	1966-03-17	Novo Terapeutisk Labor As	Verfahren zur Herstellung von Insulinloesungen
GB1042194A (en)	1962-04-30	1966-09-14	Olin Mathieson	Insulin preparations
US3528960A (en)	1968-10-07	1970-09-15	Lilly Co Eli	N-carboxyaroyl insulins
US3868358A (en)	1971-04-30	1975-02-25	Lilly Co Eli	Protamine-insulin product
GB1492997A (en)	1976-07-21	1977-11-23	Nat Res Dev	Insulin derivatives
JPS5767548A (en)	1980-10-14	1982-04-24	Shionogi & Co Ltd	Insulin analog and its preparation
FI78616C (fi)	1982-02-05	1989-09-11	Novo Industri As	Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
PH25772A (en)	1985-08-30	1991-10-18	Novo Industri As	Insulin analogues, process for their preparation
NZ222907A (en)	1986-12-16	1990-08-28	Novo Industri As	Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5605884A (en)	1987-10-29	1997-02-25	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Factor VIII formulations in high ionic strength media
US4877608A (en)	1987-11-09	1989-10-31	Rorer Pharmaceutical Corporation	Pharmaceutical plasma protein formulations in low ionic strength media
JPH01254699A (ja)	1988-04-05	1989-10-11	Kodama Kk	インスリン誘導体及びその用途
DE3827533A1 (de)	1988-08-13	1990-02-15	Hoechst Ag	Pharmazeutische zubereitung zur behandlung des diabetes mellitus
JPH04502465A (ja)	1988-12-23	1992-05-07	ノボ　ノルディスク　アクティーゼルスカブ	ヒトインシュリン類似物質
NZ232375A (en)	1989-02-09	1992-04-28	Lilly Co Eli	Insulin analogues modified at b29
IT1240314B (it)	1989-09-28	1993-12-07	Immunobiology Research Institutes, Inc.	Formulazioni acquose stabilizzate di piccoli peptidi.
DE69019534T2 (de)	1989-12-21	1995-09-21	Novonordisk As	Insulinzubereitungen, die nikotinsäure oder nikotinamid enthalten.
DK45590D0 (el)	1990-02-21	1990-02-21	Novo Nordisk As
JP3193398B2 (ja)	1991-07-23	2001-07-30	サンデン株式会社	ショ−ケ−ス
WO1993012812A1 (en)	1991-12-20	1993-07-08	Novo Nordisk A/S	A stabilized pharmaceutical formulation comprising growth hormone and histidine
US6011007A (en)	1993-09-17	2000-01-04	Novo Nordisk A/S	Acylated insulin
US6869930B1 (en)	1993-09-17	2005-03-22	Novo Nordisk A/S	Acylated insulin
ATE204882T1 (de) *	1993-09-17	2001-09-15	Novo Nordisk As	Acyliertes insulin
US5652216A (en)	1994-05-26	1997-07-29	Novo Nordisk A/S	Pharmaceutical preparation
AU3562195A (en)	1994-10-04	1996-04-26	Novo Nordisk A/S	Preparations containing aspb28 human insulin and nicotinamide
US5646242A (en)	1994-11-17	1997-07-08	Eli Lilly And Company	Selective acylation of epsilon-amino groups
US5830999A (en)	1995-01-26	1998-11-03	Regents Of The University Of California	Stabilization of insulin through ligand binding interations
ATE245659T1 (de)	1995-03-17	2003-08-15	Novo Nordisk As	Insulinabkömmlinge
US6251856B1 (en)	1995-03-17	2001-06-26	Novo Nordisk A/S	Insulin derivatives
EP2275119B1 (en)	1995-07-27	2013-09-25	Genentech, Inc.	Stable isotonic lyophilized protein formulation
US6451970B1 (en)	1996-02-21	2002-09-17	Novo Nordisk A/S	Peptide derivatives
US5898267A (en) *	1996-04-10	1999-04-27	Mcdermott; Kevin	Parabolic axial lighting device
US5866538A (en)	1996-06-20	1999-02-02	Novo Nordisk A/S	Insulin preparations containing NaCl
JP3300368B2 (ja)	1996-07-11	2002-07-08	ノボノルディスクアクティーゼルスカブ	選択的アシル化方法
US5905140A (en)	1996-07-11	1999-05-18	Novo Nordisk A/S, Novo Alle	Selective acylation method
US5763401A (en)	1996-07-12	1998-06-09	Bayer Corporation	Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
EP0821006B1 (de)	1996-07-26	2004-04-21	Aventis Pharma Deutschland GmbH	Insulinderivate mit erhöhter Zinkbindung
IL119029A0 (en)	1996-08-07	1996-11-14	Yeda Res & Dev	Long-acting drugs and pharamaceutical compositions comprising them
US5898067A (en) *	1997-02-07	1999-04-27	Novo Nordisk A/S	Crystallization of proteins
ES2260832T3 (es) *	1997-03-20	2006-11-01	Novo Nordisk A/S	Cristales de insulina desprovistos de zinc utilizados en composiciones pulmonares.
DE69806582T2 (de)	1997-03-20	2003-02-13	Novo Nordisk A/S, Bagsvaerd	Verfahren zur herstellung eines therapeutischen puders durch copräzipitation von insulin und einem absorptionsverstärker
JP2001518916A (ja)	1997-03-20	2001-10-16	ノボノルディスクアクティーゼルスカブ	結晶インスリンを含有する肺投与のための治療用粉末調合物
US7097845B2 (en)	1997-04-23	2006-08-29	Jacob Sten Petersen	Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
EP1283051B1 (en)	1997-06-13	2006-06-14	Eli Lilly And Company	Stable insulin formulations
IL135400A0 (en) *	1997-10-24	2001-05-20	Novo Nordisk As	Aggregates of human insulin derivatives
BR9813111A (pt)	1997-10-24	2000-08-15	Lilly Co Eli	Composições de insulina insolúveis
US20020155994A1 (en)	1997-10-24	2002-10-24	Svend Havelund	Aggregates of human insulin derivatives
US6451762B1 (en)	1997-10-24	2002-09-17	Novo Nordisk A/S	Aggregates of human insulin derivatives
ZA989744B (en)	1997-10-31	2000-04-26	Lilly Co Eli	Method for administering acylated insulin.
CO4970787A1 (es)	1997-12-23	2000-11-07	Lilly Co Eli	Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
AU1870099A (en)	1998-01-09	1999-07-26	Novo Nordisk A/S	Stabilised insulin compositions
ATE218364T1 (de)	1998-10-16	2002-06-15	Novo Nordisk As	Stabile konzentrierte insulin präparationen zur pulmonaren verabreichung
US6211144B1 (en)	1998-10-16	2001-04-03	Novo Nordisk A/S	Stable concentrated insulin preparations for pulmonary delivery
ATE365052T1 (de)	1999-02-22	2007-07-15	Univ Connecticut	Neue albuminfreie faktor viii formulierungen
WO2000064940A1 (en)	1999-04-27	2000-11-02	Eli Lilly And Company	Insulin crystals for pulmonary administration
GB9930882D0 (en)	1999-12-30	2000-02-23	Nps Allelix Corp	GLP-2 formulations
DE10022092A1 (de)	2000-05-08	2001-11-15	Aventis Behring Gmbh	Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US6652886B2 (en)	2001-02-16	2003-11-25	Expression Genetics	Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
DE10114178A1 (de)	2001-03-23	2002-10-10	Aventis Pharma Gmbh	Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US20030119734A1 (en)	2001-06-28	2003-06-26	Flink James M.	Stable formulation of modified GLP-1
CA2468100A1 (en)	2001-12-20	2003-07-03	Eli Lilly And Company	Insulin molecule having protracted time action
AU2003208316A1 (en)	2002-03-13	2003-09-22	Novo Nordisk A/S	Minimising body weight gain in insulin treatment
EP1506230B1 (en)	2002-05-07	2011-01-19	Novo Nordisk A/S	Soluble formulations comprising monomeric insulin and acylated insulin
US20050232899A1 (en)	2002-05-31	2005-10-20	Aradigm Corporation	Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US20040002451A1 (en)	2002-06-20	2004-01-01	Bruce Kerwin	Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
KR100615389B1 (ko)	2002-08-23	2006-08-25	(주)헬릭서	다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품
US20060198894A1 (en)	2002-10-29	2006-09-07	Johanna Bentz	Stabilized, solid-state polypeptide particles
US20040138099A1 (en)	2002-11-29	2004-07-15	Draeger Eberhard Kurt	Insulin administration regimens for the treatment of subjects with diabetes
JPWO2004069259A1 (ja)	2003-02-07	2006-05-25	味の素株式会社	糖尿病治療剤
CN100422328C (zh)	2003-02-19	2008-10-01	诺瓦提斯公司	在人转移性肿瘤细胞中表达的糖蛋白抗原sima135
EA200501422A1 (ru)	2003-03-04	2006-04-28	Дзе Текнолоджи Девелопмент Компани Лтд.	Длительнодействующая инъецируемая композиция инсулина и способы её изготовления и применения
WO2004112828A1 (en)	2003-06-25	2004-12-29	Novo Nordisk Health Care Ag	Liquid composition of factor vii polypeptides
US20050054818A1 (en)	2003-07-02	2005-03-10	Brader Mark Laurence	Crystalline compositions for controlling blood glucose
EP2264065B1 (en) *	2003-08-05	2017-03-08	Novo Nordisk A/S	Novel insulin derivatives
KR101186851B1 (ko)	2003-08-05	2012-10-02	노보 노르디스크 에이/에스	신규의 인슐린 유도체
CA2534028A1 (en)	2003-08-14	2005-02-24	Novo Nordisk Health Care Ag	Liquid, aqueous pharmaceutical composition of factor vii polypeptides
WO2005021022A2 (en)	2003-09-01	2005-03-10	Novo Nordisk A/S	Stable formulations of peptides
ES2229931B1 (es)	2003-10-03	2006-01-16	Grifols, S.A.	Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
JP2007532096A (ja)	2003-11-14	2007-11-15	ノボ　ノルディスク　アクティーゼルスカブ	アシル化されたインスリンの製造方法
JP4845741B2 (ja)	2003-12-23	2011-12-28	ファルマシアコーポレーション	安定な成長ホルモン液体製剤
US7279457B2 (en)	2004-03-12	2007-10-09	Biodel, Inc.	Rapid acting drug delivery compositions
MXPA06014079A (es)	2004-06-01	2007-02-15	Ares Trading Sa	Metodo para estabilizar proteinas.
MX2007001663A (es)	2004-08-12	2007-04-10	Schering Corp	Formulacion de interferon pegilado estable.
SI1778723T1 (sl)	2004-08-17	2013-02-28	Regeneron Pharmaceuticals, Inc.	Formulacije IL-1 antagonista
ES2575984T3 (es)	2004-11-12	2016-07-04	Novo Nordisk A/S	Formulaciones estables de péptidos que contienen un análogo de GLP-1 acilado y una insulina basal
CN101060856B (zh)	2004-11-22	2011-01-19	诺和诺德公司	可溶、稳定的含胰岛素制剂
CA2593112A1 (en)	2005-01-21	2006-07-27	Alza Corporation	Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion
ES2428510T3 (es) *	2005-02-02	2013-11-08	Novo Nordisk A/S	Derivados de insulina
US20090074882A1 (en)	2005-12-28	2009-03-19	Novo Nordisk A/S	Insulin compositions and method of making a composition
EP1991576B1 (en)	2006-02-27	2010-09-29	Novo Nordisk A/S	Insulin derivatives
AU2007238114B2 (en)	2006-04-12	2010-10-14	Biodel, Inc.	Rapid acting and long acting insulin combination formulations
AU2007247109B2 (en)	2006-05-09	2012-03-15	Novo Nordisk A/S	Insulin derivative
ES2744384T3 (es)	2007-06-13	2020-02-24	Novo Nordisk As	Formulación farmacéutica que comprende un derivado de insulina
PT2597103T (pt)	2007-11-16	2017-02-08	Novo Nordisk As	Composições farmacêuticas contendo insulina e um péptido insulinotrófico
TWI451876B (zh)	2008-06-13	2014-09-11	Lilly Co Eli	聚乙二醇化之離脯胰島素化合物

2004
- 2004-07-22 EP EP10174490.2A patent/EP2264065B1/en not_active Expired - Lifetime
- 2004-07-22 EP EP09165072A patent/EP2107069B1/en not_active Expired - Lifetime
- 2004-07-22 AU AU2004261353A patent/AU2004261353B2/en active Active
- 2004-07-22 BR BRPI0413276A patent/BRPI0413276B8/pt active IP Right Grant
- 2004-07-22 WO PCT/DK2004/000511 patent/WO2005012347A2/en active Application Filing
- 2004-07-22 MX MXPA06001283A patent/MXPA06001283A/es active IP Right Grant
- 2004-07-22 CA CA2531988A patent/CA2531988C/en not_active Expired - Fee Related
- 2004-07-22 EP EP04739008A patent/EP1660531A2/en not_active Withdrawn
- 2004-07-22 JP JP2006522233A patent/JP4463814B2/ja not_active Expired - Lifetime
- 2004-07-22 KR KR1020067002551A patent/KR101159559B1/ko active Protection Beyond IP Right Term
- 2004-07-22 PL PL09165072T patent/PL2107069T3/pl unknown
2006
- 2006-01-05 IL IL172980A patent/IL172980A/en active Protection Beyond IP Right Term
- 2006-01-30 US US11/343,005 patent/US7615532B2/en active Active
- 2006-03-02 NO NO20061026A patent/NO340925B1/no active Protection Beyond IP Right Term
2008
- 2008-12-29 RU RU2008152033/04A patent/RU2518460C2/ru active
2009
- 2009-09-16 US US12/560,833 patent/US8828923B2/en not_active Expired - Lifetime
2010
- 2010-02-10 AU AU2010200497A patent/AU2010200497B2/en active Active
2013
- 2013-03-28 CY CY20131100259T patent/CY1113850T1/el unknown
- 2013-06-10 LU LU92213C patent/LU92213I2/fr unknown
- 2013-06-11 BE BE2013C035C patent/BE2013C035I2/fr unknown
- 2013-06-19 BE BE2013C038C patent/BE2013C038I2/fr unknown
- 2013-06-19 LU LU92226C patent/LU92226I2/xx unknown
- 2013-07-04 CY CY2013027C patent/CY2013027PI2/el unknown
- 2013-07-04 FR FR13C0035C patent/FR13C0035I2/fr active Active
- 2013-07-05 FR FR13C0038C patent/FR13C0038I1/fr active Active
- 2013-07-08 CY CY2013029C patent/CY2013029PI1/el unknown
- 2013-07-18 HU HUS1300033C patent/HUS1300033I1/hu unknown
2014
- 2014-08-06 US US14/453,276 patent/US20140349925A1/en not_active Abandoned
2018
- 2018-01-11 NO NO2018002C patent/NO2018002I2/no unknown
- 2018-01-11 NO NO2018003C patent/NO2018003I1/no unknown
2023
- 2023-12-28 CY CY2013029C patent/CY2013029I2/el unknown
2024
- 2024-01-16 NO NO2024003C patent/NO2024003I1/no unknown
- 2024-01-16 NO NO2024004C patent/NO2024004I1/no unknown
- 2024-01-31 CY CY2013027C patent/CY2013027I2/el unknown

Also Published As

Publication number	Publication date
AU2010200497A1 (en)	2010-03-04
CA2531988C (en)	2016-06-28
NO2024003I1 (no)	2024-01-16
LU92213I2 (fr)	2013-08-23
EP2107069B1 (en)	2013-01-16
NO2018002I2 (no)	2018-08-20
BRPI0413276B1 (pt)	2020-03-03
JP4463814B2 (ja)	2010-05-19
NO2018003I1 (no)	2018-01-11
CY1113850T1 (el)	2015-11-04
KR20060132543A (ko)	2006-12-21
FR13C0038I1 (fr)	2013-08-09
RU2518460C2 (ru)	2014-06-10
MXPA06001283A (es)	2006-04-11
RU2008152033A (ru)	2010-07-10
US20140349925A1 (en)	2014-11-27
NO340925B1 (no)	2017-07-17
AU2010200497B2 (en)	2014-10-23
NO2024004I1 (no)	2024-01-16
CY2013027I1 (el)	2024-09-20
PL2107069T3 (pl)	2013-06-28
LU92226I9 (el)	2018-11-19
BRPI0413276A (pt)	2006-10-10
JP2007523881A (ja)	2007-08-23
WO2005012347A3 (en)	2005-04-14
EP1660531A2 (en)	2006-05-31
CY2013029PI2 (el)	2015-11-04
FR13C0035I2 (fr)	2014-03-07
US7615532B2 (en)	2009-11-10
US20100009899A1 (en)	2010-01-14
IL172980A0 (en)	2006-06-11
CY2013027PI1 (el)	2015-11-04
CY2013027I2 (el)	2024-09-20
EP2264065B1 (en)	2017-03-08
AU2004261353A1 (en)	2005-02-10
US20060183668A1 (en)	2006-08-17
IL172980A (en)	2013-10-31
WO2005012347A2 (en)	2005-02-10
BE2013C035I2 (el)	2023-12-14
EP2107069A3 (en)	2009-11-25
BE2013C038I2 (el)	2023-12-14
CA2531988A1 (en)	2005-02-10
LU92213I9 (el)	2018-11-19
NO20061026L (no)	2006-03-02
EP2264065A2 (en)	2010-12-22
LU92226I2 (fr)	2015-04-29
NO2018002I1 (no)	2018-01-11
BRPI0413276B8 (pt)	2021-05-25
HUS1300033I1 (hu)	2016-08-29
EP2264065A3 (en)	2011-07-27
CY2013029I1 (el)	2024-09-20
CY2013029I2 (el)	2024-09-20
KR101159559B1 (ko)	2012-06-26
CY2013027PI2 (el)	2015-11-04
EP2107069A2 (en)	2009-10-07
US8828923B2 (en)	2014-09-09
AU2004261353B2 (en)	2009-12-10
FR13C0035I1 (el)	2013-08-09

Publication	Publication Date	Title
CY2013027I1 (el)	2024-09-20	Νεα παραγωγα ινσουλινης
ATE340782T1 (de)	2006-10-15	Piperidinbenzolsulfonamidderivate
CY2015036I2 (el)	2016-06-22	Νεα παραγωγα οξαζολιδινονης
ATE420066T1 (de)	2009-01-15	Amidoacetonitrilderivate
ATE352550T1 (de)	2007-02-15	Chinazolinderivate
DK2609947T3 (da)	2020-07-06	Plasterlignende infusionsapparat
IS8108A (is)	2005-10-31	Ný efnasambönd
DE602004017700D1 (de)	2008-12-24	Transmukosen verabreichung
ATE395345T1 (de)	2008-05-15	Imidazol-4-yl-ethynyl-pyridin-derivate
IS8364A (is)	2006-03-20	N-þíasól-2-ýl-bensamíð afleiður
IS8180A (is)	2005-12-14	Nýjar besímídasólafleiður
IS8228A (is)	2006-01-11	Ný asetídínefnasambönd
DK2107069T3 (da)	2013-04-15	Nye insulinderivater
IS8292A (is)	2006-02-09	Ný efnasambönd
DE602004019555D1 (de)	2009-04-02	Heterocyclische 7-aminoalkylidenylchinolone und -naphthyridone
DK1706373T3 (da)	2010-01-18	Amidoacetonitrilderivater
IS8045A (is)	2005-09-26	Púrín-6-ón-afleiður
FI20021817A (fi)	2004-04-15	Kanyyli
UA6623S (uk)	2002-11-15	Шприц
FI20030224A0 (fi)	2003-02-13	Uudet farmaseuttiset käytöt
SE0301797D0 (sv)	2003-06-19	New use V
SE0300106D0 (sv)	2003-01-16	New use
SE0302332D0 (sv)	2003-08-29	New use I
IS8301A (is)	2006-02-14	Nýjar fúsíðsýruafleiður
SE0301655D0 (sv)	2003-06-05	New combination